

## Race Oncology

Race Oncology is a *specialty pharma* company pursuing later stage drug assets that have been overlooked by big pharma. Our first asset is a cancer chemotherapy drug called Bisantrene, which was the subject of more than 40 phase II studies before it was lost in a series of big pharma mergers during the 1990s. We intend to launch Bisantrene during calendar 2017 via a named patient program (NPP) in Europe, aimed at relapsed/refractory Acute Myeloid Leukemia (AML). We are now seeking licensing partners for all countries outside Europe.